

## DAFTAR PUSTAKA

1. Choi HM, Park MS, Youn JC. Update on heart failure management and future directions. *Korean J Intern Med.* 2019;34(1):11–43.
2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J.* 2016;37(27):2129-2200m.
3. Siswanto BB, Hersunarti N, Erwinanto, Nauli SE, Lubis AC. Pedoman Tatalaksana Gagal Jantung. In: Siswanto BB, editor. Indonesia: PP PERKI; 2020. p. 1–135.
4. Juzar DA. Tata Laksana Gagal Jantung dengan Penurunan Fraksi Ejeksi. In: Yuniadi Y, Hermanto DY, Rahajoe AU, editors. *Buku Ajar Kardiovaskular*. Jilid 1. Jakarta: Sagung Seto; 2017. p. 367–88.
5. Tsutsui H, Isobe M, Ito H, Okumura K, Ono M, Kitakaze M, et al. JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure — digest version —. *Circ J.* 2019;83(10):2084–184.
6. Mann DL, Chakinala M. Heart Failure: Pathophysiology and Diagnosis. In: Jameson LJ, Kasper DL, Longo DL, Fauci AS, Hauser SL, Loscalzo J, editors. *Harrison's principle of internal medicine*. 20th ed. United States: Mc Grawa Hill Education; 2018. p. 1763–9.



oyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: The Framingham Heart Study. *Circulation.* 2002;106(24):3068–72.

8. Gheorghiade M, Sopko G, Luca L De, Velazquez EJ, Parker JD, Binkley PF, et al. Navigating the crossroads of coronary artery disease and heart failure. *Circulation*. 2006;114(11):1202–13.
9. Hasenfuss G, Mann DL. Pathophysiology of Heart Failure. In: Libby P, Bonow RO, Mann DL, Tomaselli GF, Bhatt DL, Solomon SD, editors. *Braunwald's Heart Disease*. 12th ed. Philadelphia: Elsevier; 2022. p. 913–32.
10. McDermott B, Bell D. NPY and Cardiac Diseases. *Curr Top Med Chem*. 2007;7(17):1692–703.
11. Ross B, McKendy K, Giaid A. Role of urotensin II in health and disease. *Am J Physiol - Regul Integr Comp Physiol*. 2010;298(5):1156–72.
12. Scarabelli T, Stephanou A, Rayment N, Pasini E, Comini L, Curello S, et al. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. *Circulation*. 2001;104(3):253–6.
13. Chareonthaitawee P, Gersh BJ, Araoz PA, Gibbons RJ. Revascularization in severe left ventricular dysfunction: The role of viability testing. *J Am Coll Cardiol*. 2005;46(4):567–74.
14. Niazi M, Galehdar N, Jamshidi M, Mohammadi R, Moayyedkazemi A. A Review of the Role of Statins in Heart Failure Treatment. *Curr Clin Pharmacol*. 2019;15(1):30–7.



ehagen U, Benson L, Edner M, Dahlström U, Lund LH. Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the

Swedish heart failure registry. *Circ Hear Fail*. 2015;8(2):252–60.

16. Javaheri A, Rader DJ, Javaheri S. Statin therapy in heart failure is it time for a second look? *Hypertension*. 2014;63(5):909–10.
17. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. *J Lipid Res*. 1980;21(5):505–17.
18. Kelly JP, Dunning A, Schulte PJ, Fiuzat M, Leifer ES, Fleg JL, et al. Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION. *JACC Hear Fail*. 2016;4(8):617–24.
19. Bonsu KO, Kadirvelu A, Reidpath DD. Statins in heart failure: Do we need another trial? *Vasc Health Risk Manag*. 2013;9(1):303–19.
20. Djulbegovic B, Hozo I. Statins for primary prevention of cardiovascular disease. *Ann Intern Med*. 2019;171(1):73–4.
21. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. *Clin Ther*. 2009;31(2):236–44.
22. Kazi DS, Penko JM, Bibbins-Domingo K. Statins for Primary Prevention of Cardiovascular Disease: Review of Evidence and Recommendations for Clinical practice. *Med Clin North Am*. 2017;101(4):689–99.



laee M, Ferns GAA, Ghayour-Mobarhan M. Heat shock proteins and cardiovascular disease. 1st ed. Vol. 64, *Advances in Clinical Chemistry*. Elsevier

Inc.; 2014. 73–115 p.

24. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. *Am J Cardiol.* 2004;93(9):1124–9.
25. Gastelurrutia P, Lupón J, De Antonio M, Urrutia A, Díez C, Coll R, et al. Statins in heart failure: The paradox between large randomized clinical trials and real life. *Mayo Clin Proc.* 2012;87(6):555–60.
26. Lipinski MJ, Caughen CA, Biondi-Zoccai GGL, Abbate A, Vrtovec B, Khan B V., et al. Meta-Analysis of Randomized Controlled Trials of Statins Versus Placebo in Patients With Heart Failure. *Am J Cardiol.* 2009;104(12):1708–16.
27. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJP, Lewis SJ, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: Subgroup analysis of the Treating to New Targets (TNT) study. *Circulation.* 2007;115(5):576–83.
28. Oikawa T, Sakata Y, Nochioka K, Miura M, Tsuji K, Onose T, et al. Prognostic impact of statin intensity in heart failure patients with ischemic heart disease: A report from the CHART-2 (Chronic Heart Failure Registry and Analysis in the Tohoku District 2) study. *J Am Heart Assoc.* 2018;7(6).
29. Ford I, Ph D, Murray H, Sc M, Packard CJ, Sc D, et al. Long-Term Follow-up the West of Scotland Coronary Prevention Study. *New Engl J Med.* 07;357:1477–86.
- llejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard



CJ, et al. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: Analyses from the WOSCOPS (West of Scotland coronary p. Circulation. 2017;136(20):1878–91.

31. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR. The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. *Eur Heart J*. 2011;32(20):2525–32.
32. Kjekshus J, Pedersen TR, Olsson AG, Færgeman O, Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. *J Card Fail*. 1997;3(4):249–54.
33. Ballo P, Balzi D, Barchielli A, Turco L, Franconi F, Zuppiroli A. Gender differences in statin prescription rates, adequacy of dosing, and association of statin therapy with outcome after heart failure hospitalization: A retrospective analysis in a community setting. *Eur J Clin Pharmacol*. 2016;72(3):311–9.
34. Edoardo Gronda, Alberto Aronica, Marco Visconti, Antonio Di Malta, Daniela Pini, Maurizio Mangiavacchi, Bruno Andreuzzi, Annamaria Municinò, Stefano Genovese EM. [Gender differences of at risk patients with overt heart failure in the real world of general practice. Data from the GIPSI (Gestione Integrata Progetto Scompenso in Italia) registry]. *G Ital Cardiol*. 2010;11:233–8.
35. Siri A. Effect of gender difference in management of heart failure patients in Jeddah, Saudi Arabia. *Hear Views*. 2011;12(1):18.



36. Chen CY, Lee CH, Lin HW, Lin SH, Li YH. Impact of infection-related admission in patients with heart failure: a 10 years national cohort study. *Sci Rep.* 2023;13(1):1–10.
37. Franco-Peláez JA, Esteban-Lucia L, Zambrano Chacón M de los Á, Pello-Lázaro AM, Rodriguez AMV, Roca LN, et al. Statin use is associated with reduced mortality after respiratory viral infection. *ERJ Open Res.* 2021;7(1):1–8.
38. Rothberg MB, Bigelow C, Pekow PS, Lindenauer PK. Association between statins given in hospital and mortality in pneumonia patients. *J Gen Intern Med.* 2012;27(3):280–6.
39. Fang WT, Li HJ, Zhang H, Jiang S. The role of statin therapy in the prevention of atrial fibrillation: A meta-analysis of randomized controlled trials. *Br J Clin Pharmacol.* 2012;74(5):744–56.
40. Goldberger JJ, Subacius H, Schaechter A, Howard A, Berger R, Shalaby A, et al. Effects of Statin Therapy on Arrhythmic Events and Survival in Patients With Nonischemic Dilated Cardiomyopathy. *J Am Coll Cardiol.* 2006;48(6):1228–33.
41. Ohte N, Little WC. Statins beneficial for heart failure with preserved ejection fraction but not heart failure with reduced ejection fraction? *Circ J.* 15;79(3):508–9.



gers JK, Jhund PS, Perez AC, Böhm M, Cleland JG, Gullestad L, et al. Effect of rosuvastatin on repeat heart failure hospitalizations: The CORONA trial

(controlled rosuvastatin multinational trial in heart failure). JACC Hear Fail. 2014;2(3):289–97.

43. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, et al. Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After an Acute Coronary Syndrome in the PROVE IT-TIMI 22 Study. J Am Coll Cardiol. 2006;47(11):2326–31.
44. GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1231–9.
45. Anderson JL, May HT, Le VT, Muhlestein JB, Horne BD, Bair TL, et al. Impact of Statin Therapy in Heart Failure Patients. JACC Adv. 2023;2(4):100385.
46. Go AS, Lee WY, Yang J, Lo JC, Gurwitz JH. Statin therapy and risks for death and hospitalization in chronic heart failure. Jama. 2006;296(17):2105–11.

